

10th April, 2017

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Dear Sir/Madam,

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 13 of the Listing Regulations - Statement of Investor complaints


Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the Statement of Investor Complaints for the quarter ended on 31st March, 2017 as under:

#	Details of Investor Complaints	Number of Complaints
1.	Pending at the beginning of the quarter as on 01.01.2017	0
2.	Received during the quarter ended 31.03.2017	11
3.	Disposed off during the quarter ended 31.03.2017	11
4.	Remaining Unresolved at the end of the quarter ended 31.03.2017	0

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
for AJANTA PHARMA LIMITED



GAURANG SHAH
Sr. G.M. - Legal &
Company Secretary